Press Releases CRISPR Therapeutics AG

Equities

CRSP

CH0334081137

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
53.91 ^USD	+0.34%		-2.07%	-13.88%

04-18	Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating	MT
04-17	Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene and Cell Therapy 2024 Annual Meeting	04-23	AQ
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting	04-22	AQ
Harvard University: How to realize immense promise of gene editing	04-17	AQ
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference	04-03	AQ
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting	04-01	AQ
Recent Appellate Decision Overturns Revocations Of Broad Institute CRISPR-Cas9 Patents	03-26	AQ
CRISPR Therapeutics Proposes New Appointment to the Board of Directors	03-13	AQ
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	02-21	AQ
CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit	02-15	AQ
CRISPR Therapeutics - European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia	02-14	AQ
CRISPR Therapeutics Announces $280 Million Registered Direct Offering	02-13	AQ
Vertex secures European approval for CRISPR cell therapy	02-13	AQ
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)	02-13	AQ
CRISPR Eyes Autoimmune Disease: What Are The Implications?	01-31	AQ
Biomay Announces its Successful Support of Approval of First CRISPR/Cas9-based Therapy	01-29	AQ
CRISPR Gene Editing For Sickle Cell Disease: A New Era Of Hope	01-29	AQ
CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia	01-16	AQ
First CRISPR Therapy Approved For Use In The UK	01-10	AQ
CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook	01-08	AQ
CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	01-03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases CRISPR Therapeutics AG

Equities

CRSP

CH0334081137

Press Releases

Filters